Articles

Pellini named BioAdvance Entrepreneur-in-Residence

The Biotechnology Greenhouse of Southeastern Pennsylvania BioAdvance recently announced the selection of Dr. Michael Pellini as the organization’s inaugural Entrepreneur-in-Residence. Part of a $2-billion initiative by the Commonwealth of Pennsylvania to
Written byRandall C Willis
| 2 min read

PHILADELPHIA—The Biotechnology Greenhouse of Southeastern Pennsylvania BioAdvance recently announced the selection of Dr. Michael Pellini as the organization's inaugural Entrepreneur-in-Residence. Part of a $2-billion initiative by the Commonwealth of Pennsylvania to stimulate the economy by supporting life sciences technologies and entrepreneurs, BioAdvance's mission is to transform the region's strengths in biomedical R&D into commercial opportunities by providing venture capital funding and hands-on business planning and development support.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a single cell surrounded by small molecular particles in a red biological environment.
Measuring mRNA and protein together at single cell resolution can uncover tumor-specific signaling activity and immune features.
Illustration of an antibody intertwined with a DNA double helix.
Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.
Digital illustration of the human digestive system highlighting the liver, stomach, and intestines.
Explore how human gut-liver models can improve the translation of preclinical findings into clinical pharmacokinetic predictions.